GTx names new chief medical officer

Memphis-based GTx Inc. has named Diane Young vice president and chief medical officer. Young, a certified medical oncologist, most recently spent 12 years in global and regional leadership with Novartis. She was also vice president of global development at R.W. Johnson Pharmaceutical Research Institute. “Dr. Young brings a significant amount of experience to GTx, including a proven track record of developing successful cancer therapies,” said Marc Hanover, CEO of GTx. “We are very fortunate…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: Available online 19 April 2019Source: Seminars in Cancer BiologyAuthor(s): Lingzhi Li, Zhuoyu Bi, Priya Wadgaonkar, Yongju Lu, Qian Zhang, Yao Fu, Chitra Thakur, Li Wang, Fei ChenAbstractAt present, the belief that genetic mutations control every aspect of tumorigenesis is still very popular. Even for the highly debated “bad luck” theory of cancers, it ascertained that random mutation of genes during the self-renewal of somatic stem cells is responsible for cancer initiation. Logically, most of the new therapeutic strategies so far, from molecular targeting to precision medicine or personalize...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 April 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Jingwen Shi, Shuiping Liu, Yuan Yu, Changyu He, Lianjiang Tan, Yu-Mei ShenAbstractDevelopment of polymer-drug conjugate capable of controlled drug release is urgently needed for gastric cancer therapy. Herein, arginine-glycine-aspartic acid (RGD)-decorated polyethylene glycol (PEG)-paclitaxel (PTX) conjugates containing disulfide linkage were synthesized. The amphiphilic PEG-PTX conjugates were found to assemble into micelles (RGD@Micelles), which would be decomposed under the reduction of glutathione (GSH) and finally ...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: Available online 18 April 2019Source: Pharmacological ResearchAuthor(s): Filipe J. Teixeira, Heitor O. Santos, Scott L. Howell, Gustavo D. PimentelAbstractCancer remains a public health challenge in the identification and development of ideal pharmacological therapies and dietary strategies. The use of whey protein as a dietary strategy is widespread in the field of oncology. The two types of whey protein, sweet or acid, result from several processing techniques and possess distinct protein subfraction compositions. Mechanistically, whey protein subfractions have specific anti-cancer effects. Alpha-lactal...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 April 2019Source: Nano TodayAuthor(s): Arif Gulzar, Jiating Xu, Chen Wang, Fei He, Dan Yang, Shili Gai, Piaoping Yang, Jun Lin, Dayong Jin, Bengang XingAbstractThe tumour mass is made up of not only of a heterogeneous population of cancer cells nonetheless also a mixture of resident as well as the infiltrating host cells, secreted factors besides extracellular matrix proteins, together recognized as the tumour microenvironment (TME). Tumour development is overwhelmingly affected through the dealings of cancer cells with their environment which eventually conclude whether the primary tu...
Source: Nano Today - Category: Nanotechnology Source Type: research
The phosphoinositide 3-kinase (PI3K) signaling pathway is frequently activated in human cancer due to activating mutations in PI3Ks or the loss of phosphatase and tensin homologue (PTEN) function. In addition to its canonical role as a regulator of cellular proliferation and survival, the PI3K pathway has been implicated in promoting resistance to immune-based anti-cancer therapies. To further define how PI3K signaling may promote tumor cell immune escape, we examined the impact of PI3K inhibition and activation on the induction of MHC class I (MHCI) and II (MHCII) molecules by interferon-gamma (IFN-g).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
It was over one hundred years ago that immunotherapy for cancer was first explored by Dr William Coley with the intratumoral injection of bacterial extracts that resulted in tumor regression in select cases. The emergence of surgical procedures, radiation therapy, and chemotherapy eventually became the mainstay of cancer therapies and relegated immune treatments as an unfulfilled pipedream. Nevertheless, it has been apparent that the immune system can play a role in tumor biology as evident by cases of spontaneous tumor regression and increased cancer incidence among immunosuppressed patients.
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Tags: Preface Source Type: research
When a prostate cancer staging exam is needed, clinicians at one Australian...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In this study, three PEGylated acid-sensitive prodrugs DOX-PEG-DOX with different molecular weights, were prepared via Schiff-base reaction between aldehyde-modified PEG and the amino groups of doxorubicin (DOX). This kind of amphiphilic polymeric prodrug could be self-assemble into nanoparticles in aqueous solution. The average particle size and morphologies of the prodrug nanoparticles under different pH conditions were observed by dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively. It turned out that the nanoparticles could be kept stable in the physiological environment, but degrade...
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research
(Medical College of Georgia at Augusta University) Identifying a protein that plays a key role in cancer cell growth is a first step toward the development of a targeted cancer therapy. It is especially promising when this protein is dispensable for the growth of normal cells. Their discovery that UNC45A fits these criteria has researchers, led by Dr. Ahmed Chadli, of the Georgia Cancer Center at Augusta University, excited about potential new cancer therapeutic strategies involving the inhibition of UNC45A.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In conclusion, our study provides a protocol of producing a biologically active survivin-targeting macromolecule, T34A-C84A-dNSur-His, which can be used as a tool for studying the molecular and cellular roles of survivin in cells. T34A-C84A-dNSur-His is also a potential therapeutic agent for augmenting cancer therapy.
Source: Protein Expression and Purification - Category: Biochemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Health Management | Pharmaceuticals